香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因依賴該等內容而引致的任何損失承擔任何責任。 本公司謹此向股東及潛在投資者提供下列有關該等收購事項的補充資料。 （於開曼群島註冊成立的有限公司） （股份代號：3600） 補充公告 須予披露交易 (1) 收購目標公司74%股 份 及 (2) 認購期權及認沽期權 茲提述本公司日期為2024年11月21日的公告（「該公告」），內容有關（其中包括）收 購Hexa Ceram Company Limited（「目標公司」）合共74%股份。除非文義另有規定， 本公告所用詞彙與該公告所界定者具有相同涵義。 付款 買賣協議A項下收購銷售股份A之代價須由買方在完成A時於完成日期A支付。 買賣協議B項下收購銷售股份B之代價須由買方在完成B時於完成日期B支付。 承董事會命 現代牙科集團有限公司 主席兼執行董事 陳奕朗 香港，2024年11月25日 於本公告日期，本公司董事會包括執行董事陳奕朗、魏聖堅、陳奕茹、陳冠峰、陳冠斌及 陳志遠，以及獨立非執行董事張惠彬太平紳士、陳 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：3600） 須予披露交易 (1) 收購目標公司 74 % 股 份 及 期權協議 就該等收購事項而言，在2024年11月21日（交易時段後）簽訂該等買賣協議的同 時，買方（作為期權持有人）、Meekiatichaikun先生（作為授予人）及本公司（作為 擔保人）亦訂立期權協議，據此 (i)Meekiatichaikun先生已向買方授出認購期權， 以使其（及╱或其指定人士）購買部分或全部由Meekiatichaikun先生所持有的期權 股份；及(ii)買方已向Meekiatichaikun先生授出認沽期權，以要求買方（及╱或其 指定人士）購買部分或全部由Meekiatichaikun先生所持有的期權股份。 (2) 認購期權及認沽期權 該等買賣協議 買賣協議A 於2024年11月21日（交易時段後），買方、賣方A、Meekiatichaikun先生（作為保 證人） ...

Financial Performance - For the six months ended June 30, 2024, the revenue was approximately HKD 1,701,831,000, an increase of about HKD 100,279,000 or 6.3% compared to HKD 1,601,552,000 for the same period in 2023[20]. - The gross profit margin for the six months ended June 30, 2024, was approximately 53.7%, down from 54.2% in the same period of 2023, with gross profit increasing by approximately HKD 46,672,000 or 5.4% to HKD 913,991,000[20]. - The EBITDA for the six months ended June 30, 2024, was approximately HKD 375,571,000, reflecting an increase of about HKD 5,817,000 or 1.6% compared to HKD 369,754,000 for the same period in 2023[20]. - The net profit for the six months ended June 30, 2024, was approximately HKD 214,355,000, an increase of about HKD 4,079,000 or 1.9% compared to HKD 210,276,000 for the same period in 2023[20]. - The adjusted EBITDA for the six months ended June 30, 2024, was approximately HKD 388,584,000, an increase of about HKD 18,698,000 or 5.1% compared to HKD 369,886,000 for the same period in 2023[20]. - The core business profit for the six months ended June 30, 2024, was approximately HKD 225,549,000, an increase of about HKD 15,141,000 or 7.2% compared to HKD 210,408,000 for the same period in 2023[21]. - The basic earnings per share for the six months ended June 30, 2024, were HKD 0.2259, compared to HKD 0.2213 for the same period in 2023[21]. - The board declared an interim dividend of HKD 0.08 per ordinary share for the six months ended June 30, 2024, up from HKD 0.06 for the same period in 2023[21]. Revenue Breakdown - Revenue from fixed dental appliances reached approximately HKD 1,045,387,000, an increase of about HKD 31,127,000 compared to the same period in 2023, accounting for 66.1% of total revenue[29]. - Revenue from removable dental appliances was approximately HKD 393,546,000, an increase of about HKD 42,970,000 compared to the same period in 2023, representing 24.9% of total revenue[30]. - Revenue from other customized appliances was approximately HKD 143,622,000, an increase of about HKD 4,368,000 compared to the same period in 2023, representing 9.0% of total revenue[31]. - Revenue from the European market was approximately HKD 822,914,000, an increase of about HKD 112,869,000 compared to the same period in 2023, accounting for 48.4% of total revenue[40]. - North America generated revenue of approximately HKD 385,325,000, a decrease of about HKD 8,331,000 compared to the six months ended June 30, 2023, accounting for approximately 22.6% of total group revenue[42]. - Greater China market revenue was approximately HKD 335,752,000, a decrease of about HKD 15,451,000 compared to the six months ended June 30, 2023, representing about 19.7% of total group revenue[43]. - Australia market revenue was approximately HKD 127,902,000, an increase of about HKD 3,645,000 compared to the six months ended June 30, 2023, accounting for about 7.5% of total group revenue[44]. Market Trends and Strategies - The company continues to enhance its market position through digital transformation and expansion of production facilities in Vietnam and Dongguan[19]. - The company continues to focus on digitalization trends in the dental industry to capture market share and enhance customer satisfaction[40]. - The company aims to establish a new business unit in Vietnam to serve mid-to-large dental clinic chains in North America[42]. - The company plans to strengthen its position in the Greater China market by promoting advanced innovative solutions and expanding its product portfolio[43]. - The company is focused on strategic opportunities such as acquisitions and partnerships to enhance its global leadership position in the dental market[44]. Cost and Expenses - Sales and distribution expenses increased by approximately 14.7% to HKD 230,896,000, accounting for 13.6% of total revenue, up from 12.6% in the prior year[50]. - Administrative expenses rose by 0.7% to HKD 378,833,000, representing 22.3% of total revenue, down from 23.5% in the previous year[52]. - Other operating expenses surged by 568.8% to HKD 9,283,000, primarily due to asset write-offs and foreign exchange losses[53]. - Financing costs increased by 23.7% to HKD 25,706,000, accounting for 1.5% of total revenue, compared to 1.3% in the prior year[54]. Cash Flow and Investments - Cash flow from operating activities was HKD 210,840,000, slightly down from HKD 214,283,000 in the same period last year[65]. - Cash outflow from investing activities increased to HKD 93,477,000, primarily due to expansion costs for production facilities in Vietnam[66]. - The group's capital expenditure for the review period was approximately HKD 98,145,000, primarily for factory construction and equipment upgrades[68]. - Investment in cutting-edge technology machinery for 2024 amounted to approximately HKD 45,591,000, compared to HKD 12,963,000 for the six months ended June 30, 2023[68]. - Research and development costs incurred were approximately HKD 25,415,000, representing 4.2% of the group's revenue, up from 2.4% for the six months ended June 30, 2023[68]. Financial Position - As of June 30, 2024, the group's bank borrowings were approximately HKD 701,844,000, an increase from HKD 676,191,000 as of December 31, 2023[68]. - The debt ratio as of June 30, 2024, was approximately 15%, down from 16% as of December 31, 2023, indicating a stable financial position[68]. - The company’s total assets less current liabilities amounted to HKD 3,445,818 as of June 30, 2024, compared to HKD 3,397,873 as of December 31, 2023[114]. - The company’s total liabilities decreased from HKD 754,772,000 to HKD 733,557,000, a reduction of 2.8%[115]. - The company’s retained earnings increased to HKD 2,098,879,000 as of June 30, 2024, compared to HKD 1,883,746,000, an increase of 11.4%[116]. Shareholder Information - The board declared an interim dividend of HKD 75,752,000, which is an increase of 32.3% from HKD 57,299,000 in the same period last year[141]. - The company repurchased 2,121,000 shares at a total cost of approximately HKD 8,542,000 (before expenses) during the six months ended June 30, 2024[106]. - The company has a stock option plan that allows for the issuance of up to 100 million shares, representing 10.6% of the issued share capital as of the interim report date[89]. - The company has no arrangements that allow directors to benefit from purchasing shares or debt securities of the company or any other entity during the six months ended June 30, 2024[101]. Related Party Transactions - The company has multiple lease agreements with related parties, ensuring transactions are based on comparable market prices[169]. - The company’s related party transactions include agreements with shareholders and directors, ensuring compliance with relevant regulations[170]. - The company maintains transparency in its related party transactions by adhering to public pricing and conditions provided to major clients[170]. Compliance and Governance - The board approved the interim condensed consolidated financial statements on August 29, 2024[185]. - The company has no significant subsequent events as of the financial statement date[185].

Financial Performance - For the six months ended June 30, 2024, the revenue was approximately HKD 1,701,831,000, an increase of about HKD 100,279,000 or 6.3% compared to HKD 1,601,552,000 for the same period in 2023[2]. - The gross profit for the same period was approximately HKD 913,991,000, reflecting an increase of about HKD 46,672,000 or 5.4% from HKD 867,319,000 in the previous year, with a gross margin of 53.7%[2]. - The EBITDA for the six months ended June 30, 2024, was approximately HKD 375,571,000, an increase of about HKD 5,817,000 or 1.6% compared to HKD 369,754,000 in the prior year[2]. - The adjusted EBITDA for the same period was approximately HKD 388,584,000, representing an increase of about HKD 18,698,000 or 5.1% from HKD 369,886,000 in 2023[2]. - The net profit for the six months ended June 30, 2024, was approximately HKD 214,355,000, an increase of about HKD 4,079,000 or 1.9% compared to HKD 210,276,000 in the previous year[2]. - Basic and diluted earnings per share for the period were both HKD 0.2259, compared to HKD 0.2213 in the same period of 2023, marking an increase of 2.1%[7]. - The company declared an interim dividend of HKD 0.08 per share for the six months ended June 30, 2024, compared to HKD 0.06 per share for the same period in 2023[2]. Market Performance - The European market accounted for 48.4% of the total revenue, with sales growth of 16.2% compared to the previous year[2]. - Revenue from the European market was HKD 822,914,000, up from HKD 710,045,000 in the previous year, indicating a growth of approximately 15.8%[17]. - The North American market generated revenue of HKD 385,325,000, a slight decrease from HKD 393,656,000 in the previous year[17]. - Revenue from the Greater China market was approximately HKD 335,752,000, a decrease of about HKD 15,451,000 compared to the six months ended June 30, 2023, accounting for 19.7% of total group revenue[53]. - The Australian market recorded revenue of approximately HKD 127,902,000, an increase of about HKD 3,645,000 compared to the six months ended June 30, 2023, representing 7.5% of total group revenue[55]. Operational Highlights - The core business profit for the six months ended June 30, 2024, was approximately HKD 225,549,000, an increase of about HKD 15,141,000 or 7.2% from HKD 210,408,000 in the previous year[2]. - For the six months ended June 30, 2024, the group produced approximately 602,485 digital solution cases in mainland China, representing a 61.1% increase from approximately 373,985 cases in the same period of 2023[5]. - The fixed dental equipment segment generated revenue of HKD 1,045,387,000, with a gross profit of HKD 584,174,000, showing a slight increase from HKD 572,769,000 in the previous year[16]. - The removable dental equipment segment recorded revenue of approximately HKD 393,546,000, representing about 24.9% of total revenue, an increase of approximately HKD 42,970,000 compared to the previous period[40]. - The other custom equipment segment, which includes orthodontic devices, generated revenue of approximately HKD 143,622,000, accounting for about 9.0% of total revenue, with a year-on-year increase of approximately HKD 4,368,000[41]. Investments and Expansion - The company has made investments in production facilities in Vietnam and Dongguan to strengthen its market positioning[1]. - The company aims to establish a new business unit in Vietnam to serve mid to large dental clinic chains in the North American market[50]. - Investment in production facilities in Dongguan Phase II and Vietnam is expected to enhance R&D capabilities and improve production solutions[58]. - The company has established a large production facility in Vietnam to mitigate risks associated with its production bases in Shenzhen and Dongguan, China[82]. Financial Position - Trade receivables increased to HKD 658,725 as of June 30, 2024, from HKD 590,220 as of December 31, 2023, reflecting a growth of 11.6%[9]. - Total assets less current liabilities amounted to HKD 3,445,818 as of June 30, 2024, compared to HKD 3,397,873 as of December 31, 2023, showing an increase of 1.4%[10]. - Non-current liabilities decreased to HKD 733,557 as of June 30, 2024, from HKD 754,772 as of December 31, 2023, a reduction of 2.8%[10]. - The total bank borrowings as of June 30, 2024, amounted to HKD 701,844,000, compared to HKD 676,191,000 as of December 31, 2023, reflecting an increase of about 3.8%[34]. - The company's debt ratio was approximately 15% as of June 30, 2024, down from 16% as of December 31, 2023, indicating a stable financial condition[76]. Employee and Governance - The company employed a total of 7,182 full-time employees as of June 30, 2024, an increase from 7,035 employees as of December 31, 2023[86]. - Total employee costs for the six months ended June 30, 2024, amounted to approximately HKD 786,274,000, compared to HKD 725,358,000 for the same period in 2023, reflecting an increase of about 8.4%[87]. - The company maintained stable relationships with employees during the review period, with no significant strikes or labor disputes affecting business operations[87]. - The company has complied with the corporate governance code as per the listing rules during the six months ended June 30, 2024[94]. - The audit committee reviewed the interim results for the six months ended June 30, 2024, ensuring adherence to accounting principles and practices[95].

Financial Performance - The company reported record high revenue of HKD 3,172 million, EBITDA of HKD 694 million, and net profit of HKD 402 million for the year ending December 31, 2023[9]. - For the year ended December 31, 2023, the revenue was approximately HKD 3,172,048,000, an increase of about 12.1% compared to HKD 2,830,088,000 in 2022[14]. - The gross profit margin for the year ended December 31, 2023, was approximately 53.6%, up from 48.9% in 2022, with gross profit increasing by about 22.9% to HKD 1,700,693,000[15]. - The EBITDA for the year ended December 31, 2023, was approximately HKD 694,471,000, representing a significant increase of about 49.9% from HKD 463,351,000 in 2022[15]. - The net profit for the year ended December 31, 2023, was approximately HKD 402,177,000, an increase of about 82.4% compared to HKD 220,549,000 in 2022[15]. - The net profit margin for the year ended December 31, 2023, was 12.7%, compared to 7.8% in 2022, reflecting a significant improvement in profitability[15]. - The company reported a significant increase in total comprehensive income, amounting to HKD 428,748 thousand, a substantial rise from HKD 52,661 thousand in 2022[191]. - The company reported a pre-tax profit of HKD 509,588,000 for 2023, an increase of 75.7% compared to HKD 290,146,000 in 2022[199]. Market Performance - The European market contributed 44.1% to the company's total revenue, making it the largest market for the company[10]. - The sales revenue from fixed dental prosthetics was approximately HKD 1,985,044,000, accounting for about 66.6% of total revenue, with an increase of approximately HKD 181,578,000 from the previous year[20]. - The sales revenue from removable dental prosthetics was approximately HKD 712,962,000, representing about 23.9% of total revenue, with an increase of approximately HKD 177,871,000 from the previous year[21]. - The North American market recorded revenue of approximately HKD 753,615,000, an increase of about HKD 44,298,000, representing 23.8% of total revenue, with a growth rate of 6.2%[30]. - The Greater China market achieved revenue of approximately HKD 713,592,000, an increase of about HKD 46,933,000, accounting for 22.5% of total revenue, despite a 4.3% depreciation of RMB against HKD[31]. - The Australian market reported revenue of approximately HKD 254,341,000, an increase of about HKD 18,530,000, representing 8.0% of total revenue, with a decline of 4.4% in AUD against HKD[32]. Strategic Initiatives - The company aims to strengthen its global leadership through strategic partnerships, acquisitions, and joint ventures[10]. - The company plans to allocate more resources to the North American market to unlock its full potential[10]. - The company is investing in production facilities in Dongguan and Vietnam to enhance overall production capacity[10]. - The company plans to establish a new business unit in Vietnam to serve mid to large dental clinic chains in North America[30]. - The company aims to strengthen its market position in Greater China by promoting advanced innovative solutions and expanding its product range[31]. - The company is positioned to capitalize on the digitalization trend in the dental industry, enhancing its digital solutions and expanding its product offerings[29]. Sustainability and Corporate Responsibility - The company is committed to sustainable practices, aiming to reduce energy consumption and waste in its manufacturing processes[10]. - The overall strategy includes a commitment to sustainability, with plans to reduce carbon emissions by 40% by 2026[70]. - The company is committed to social responsibility and sustainable growth, actively participating in community activities[135]. Employee and Governance - The company emphasizes the importance of employee health and safety, promoting fair labor practices and diversity[10]. - The company employed a total of 7,035 full-time employees as of December 31, 2023, compared to 6,830 in 2022, with total employee costs amounting to approximately HKD 1,439,045,000 for the year[64]. - The board of directors includes 5 executive directors and 4 independent non-executive directors, with terms renewed for three years starting from December 15, 2022, for executive directors[97]. - The company has established a share option scheme allowing for the issuance of shares up to 30% of the issued share capital, with a maximum of 100 million shares (10.5% of issued share capital) available for options as of the report date[101]. Risk Management - The company faces various business risks, including global economic fluctuations and geopolitical risks, which may significantly impact its financial condition and operating performance[57]. - The company continues to monitor foreign exchange risks closely, particularly with currencies such as RMB, EUR, AUD, and USD[62]. - The company has established procedures for identifying, assessing, and managing significant risks, ensuring regular monitoring and reporting to the board[164]. Financial Position - As of December 31, 2023, the group’s cash and cash equivalents amounted to approximately HKD 697,694,000, compared to HKD 444,377,000 as of December 31, 2022[47]. - The debt ratio as of December 31, 2023, was approximately 16%, a decrease from 22% in 2022, indicating a stronger financial position[54]. - The company’s retained earnings reached HKD 1,888,746,000 as of December 31, 2023, up from HKD 1,539,524,000 in 2022, marking an increase of around 22.7%[197]. - The total equity attributable to the owners of the company was HKD 2,632,279,000 in 2023, compared to HKD 2,319,952,000 in 2022, which is an increase of approximately 13.5%[194].

Financial Performance - The company's revenue for the year ended December 31, 2023, was approximately HKD 3,172,048,000, representing an increase of about 12.1% compared to HKD 2,830,088,000 in 2022[3]. - The gross profit margin for the year ended December 31, 2023, was approximately 53.6%, up from 48.9% in 2022, with gross profit increasing by approximately 22.9% to HKD 1,700,693,000[3][5]. - EBITDA for the year ended December 31, 2023, was approximately HKD 694,471,000, reflecting an increase of about 49.9% from HKD 463,351,000 in 2022[3][5]. - The net profit for the year ended December 31, 2023, was approximately HKD 402,177,000, an increase of about 82.4% compared to HKD 220,549,000 in 2022[3][5]. - Basic earnings per share for the year ended December 31, 2023, were 42.4 HKD cents, up approximately 83.5% from 23.1 HKD cents in 2022[3][5]. Dividends - The company plans to distribute a final dividend of 9.0 HKD cents per share for the year ended December 31, 2023, compared to 4.4 HKD cents in 2022, pending shareholder approval[4]. - The interim dividend per share increased to HKD 0.06 in 2023 from HKD 0.037 in 2022, while the proposed final dividend per share rose to HKD 0.09 from HKD 0.044[32]. Market Performance - Revenue from the European market for the year ended December 31, 2023, was HKD 1,399,371,000, reflecting a natural growth rate of 15.3%[6]. - The North American market generated revenue of HKD 753,615,000, with a growth rate of 6.2%[6]. - The fixed dental equipment segment generated revenue of approximately HKD 1,985,044,000, an increase of about HKD 181,578,000 from the previous year, accounting for 66.6% of total revenue[47]. - The removable dental equipment segment recorded revenue of approximately HKD 712,962,000, an increase of about HKD 177,871,000, representing 23.9% of total revenue[48]. - The other custom equipment segment achieved revenue of approximately HKD 283,865,000, an increase of about HKD 10,205,000, accounting for 9.5% of total revenue[49]. Assets and Liabilities - Non-current assets increased to HKD 2,381,523 thousand in 2023, up from HKD 2,273,309 thousand in 2022, representing a growth of 4.76%[11]. - Current assets rose to HKD 1,571,324 thousand in 2023, compared to HKD 1,265,746 thousand in 2022, marking an increase of 24.09%[11]. - Total liabilities increased to HKD 754,772 thousand in 2023 from HKD 676,139 thousand in 2022, reflecting a rise of 11.59%[12]. - The company's equity attributable to owners increased to HKD 2,643,101 thousand in 2023, up from HKD 2,333,533 thousand in 2022, indicating a growth of 13.24%[13]. - Cash and cash equivalents significantly increased to HKD 697,694 thousand in 2023 from HKD 444,377 thousand in 2022, a rise of 57.06%[11]. Research and Development - Research and development costs for 2023 amounted to HKD 43,239,000, up from HKD 40,096,000 in 2022[27]. - R&D expenses amounted to HKD 35,935,000 in 2023, an increase from HKD 32,348,000 in 2022[28]. Operational Highlights - The number of digital solutions produced in mainland China increased to approximately 857,064 cases, a rise of 55.9% from 549,736 cases in 2022, driven by greater adoption of intraoral scanners[4]. - Total sales volume for the year was 2,073,268 units, a 13.3% increase from 1,830,392 units in the previous year[52]. - The average selling price per unit increased to HKD 1,438, a slight rise of 0.8% from HKD 1,427 in the previous year[52]. Financial Management - Financing costs totaled HKD 41,222,000 in 2023, up from HKD 26,270,000 in 2022, with bank loan interest rising to HKD 38,806,000[29]. - The company's debt ratio decreased to approximately 16% as of December 31, 2023, down from 22% in 2022, reflecting a stronger financial position[79]. - The company recorded a net cash outflow from financing activities of approximately HKD 173,640,000 for the year ended December 31, 2023, which included dividend payments of HKD 99,030,000[76]. Corporate Governance - The company adhered to the corporate governance code as per the listing rules for the year ended December 31, 2023[97]. - The audit committee, consisting of three independent non-executive directors, reviewed the group's financial performance for the year ended December 31, 2023[98]. - The company's auditor confirmed that the figures in the preliminary announcement for the consolidated financial statements were consistent with the draft financial statements for the year[99]. Strategic Outlook - The company continues to focus on digital transformation and market expansion, enhancing customer and patient experiences to outperform competitors[1][2]. - The group aims to consolidate its global leadership position through strategic collaborations, acquisitions, and partnerships to expand its product offerings and distribution network[61]. - Investments in production facilities in Dongguan and Vietnam are expected to enhance the group's R&D capabilities and production solutions[61].

随着国内外老龄化阶段的到来，假牙市场成为牙科市场高速发展的一个细分赛道，而作为国内义齿加工 龙头，现代牙科也靠着全球化的"假牙生意"不断捞金。 3月11日，现代牙科披露了其2023年业绩盈喜。公司预计2023年实现收益31.25-32.25亿港元，同比增加 10.4%-14%;净利润实现3.9-4.1亿港元，同比大幅增长76.5%-85.5%。在盈喜公告中公司表示，当期净利 润创新高主要由于公司营运效率提升及牙科行业数码化趋势推动数码化解决方案个案比例增加。 从二级市场来看，投资者对于现代牙科的义齿加工主业持续增长反馈积极。从去年5月16日盘中触及阶 段性股价低点2.19港元后，现代牙科的股价便一路走高，截至今年3月13日，公司股价已达4.02港元，区 间累计增长83.56%。 据智通财经APP了解，当下全球超60%的义齿在中国生产，国内义齿加工企业数量突破4000家。对于现 代牙科来说，通过扩大市场份额、持续降本增效从日益白热化的竞争中突围才是发展的关键。 "假牙技工所"的技术逆袭 实际上，市场对于现代牙科在2023全年实现近80%净利润增长并不感到奇怪，早在去年中报业绩披露 后，现代牙科就显示出了较强的利 ...

Financial Performance - For the six months ended June 30, 2023, the revenue was approximately HKD 1,601,552,000, an increase of about HKD 173,060,000 or 12.1% compared to HKD 1,428,492,000 for the same period in 2022[19]. - The gross profit for the same period was approximately HKD 867,319,000, representing a 24.7% increase from HKD 695,334,000 in the prior year, with a gross margin of 54.2%[19]. - EBITDA for the six months ended June 30, 2023, was approximately HKD 369,754,000, an increase of 71.2% from HKD 215,929,000 in the previous year[19]. - Net profit for the period was approximately HKD 210,276,000, a significant increase of 109.3% compared to HKD 100,443,000 for the same period in 2022[19]. - The basic earnings per share for the six months ended June 30, 2023, was HKD 0.2213, up from HKD 0.1044 in the previous year[19]. - Total group revenue for the period was approximately HKD 1,601,552,000, an increase of about 12.1% compared to HKD 1,428,492,000 for the six months ended June 30, 2022[51]. - Profit before tax increased significantly to HKD 274,958,000, representing a 102.6% growth compared to HKD 135,395,000 in the previous year[119]. - Profit attributable to equity holders for the six months ended June 30, 2023, was HKD 211,201,000, compared to HKD 99,851,000 in 2022, reflecting a 112% increase[159]. Revenue Breakdown - Revenue from fixed dental materials, including crowns and bridges, was approximately HKD 1,014,260,000, an increase of about HKD 90,204,000, accounting for 67.4% of total revenue[29]. - The revenue from removable denture equipment was approximately HKD 350,576,000, an increase of about HKD 88,287,000 compared to the six months ended June 30, 2022, representing 23.3% of total group revenue[30]. - The revenue from other equipment was approximately HKD 139,254,000, an increase of about HKD 14,502,000 compared to the six months ended June 30, 2022, accounting for 9.3% of total group revenue[31]. - Revenue from the European market was approximately HKD 710,045,000, an increase of about HKD 93,615,000, accounting for 44.3% of total group revenue[41]. - Revenue from the North American market was approximately HKD 393,656,000, an increase of about HKD 31,208,000, representing 24.6% of total group revenue[44]. - The Greater China market recorded revenue of approximately HKD 351,203,000, an increase of about HKD 31,964,000 compared to the six months ended June 30, 2022, representing approximately 21.9% of the total group revenue[46]. - The Australia market generated revenue of approximately HKD 124,257,000, an increase of about HKD 11,390,000 compared to the six months ended June 30, 2022, accounting for approximately 7.8% of total group revenue[47]. - Other markets, including Indian Ocean countries, Malaysia, Taiwan, and Singapore, recorded revenue of approximately HKD 22,391,000, an increase of about HKD 4,883,000 compared to the six months ended June 30, 2022, representing approximately 1.4% of total group revenue[49]. Cost and Expenses - Selling and distribution expenses increased by about 6.0% to approximately HKD 201,369,000, accounting for about 12.6% of total group revenue[55]. - Administrative expenses rose by approximately 3.6% to about HKD 376,054,000, representing about 23.5% of total group revenue[56]. - Financing costs increased by approximately 133.6% to about HKD 20,783,000, accounting for about 1.3% of total group revenue[59]. - Income tax expenses increased by approximately 85.1% from HKD 34,952,000 for the six months ended June 30, 2022, to HKD 64,682,000 for the six months ended June 30, 2023[60]. Operational Efficiency - Adjusted EBITDA for the six months ended June 30, 2023, was HKD 369,886,000, compared to HKD 216,364,000 for the same period in 2022, reflecting an increase in operational efficiency[64]. - Net cash flow from operating activities increased significantly to HKD 214,283,000 for the six months ended June 30, 2023, from HKD 56,923,000 for the same period in 2022[66]. - Cash generated from operating activities increased to HKD 278,096,000, up from HKD 125,773,000 year-over-year, representing a growth of approximately 121%[133]. Investments and Capital Expenditures - Capital expenditures amounted to approximately HKD 57,052,000, primarily for upgrading production facilities and equipment[71]. - The company invested approximately HKD 12,963,000 in acquiring cutting-edge technology machinery and incurred R&D costs of about HKD 24,974,000 during the period[71]. - Research and development costs for the period were HKD 24,974,000, compared to HKD 22,779,000 in 2022, reflecting a focus on innovation[152]. Employee and Compensation - As of June 30, 2023, the group employed a total of 6,860 employees, an increase from 6,830 employees as of December 31, 2022[90]. - Total employee costs for the six months ended June 30, 2023, amounted to approximately HKD 725,358,000, compared to HKD 703,475,000 for the same period in 2022, reflecting an increase of about 3.5%[90]. - The group maintains a competitive compensation policy to retain employees, including salaries, discretionary bonuses, and contributions to benefit plans[90]. Shareholder Information - The board declared an interim dividend of HKD 0.060 per share, compared to HKD 0.037 per share for the same period in 2022[19]. - The company repurchased a total of 2,048,000 shares at a total cost of approximately HKD 5,523,000 (before expenses)[111]. - The highest share price during the repurchase in May 2023 was HKD 2.52, while in June 2023, it reached HKD 3.00[112]. Corporate Governance and Compliance - The company has complied with the corporate governance code as per the listing rules during the six months ending June 30, 2023[115]. - The audit committee reviewed the interim results for the six months ending June 30, 2023[116]. - The company is committed to social responsibility and community engagement through sponsorships and donations[117]. Risks and Challenges - The group faces various business risks, including global economic fluctuations and geopolitical risks, which may adversely affect its financial condition and operating performance[78]. - The group has not established any interest rate agreements or derivative transactions to hedge against interest rate fluctuations[82].

Financial Performance - For the six months ended June 30, 2023, the company's revenue was approximately HKD 1,601,552,000, an increase of HKD 173,060,000 or 12.1% compared to HKD 1,428,492,000 for the same period in 2022[2] - The gross profit for the same period was approximately HKD 867,319,000, representing an increase of HKD 171,985,000 or 24.7%, with a gross margin of 54.2% compared to 48.7% in the previous year[2] - EBITDA for the six months ended June 30, 2023, was approximately HKD 369,754,000, an increase of HKD 153,825,000 or 71.2% from HKD 215,929,000 in the same period of 2022[2] - The net profit for the period was approximately HKD 210,276,000, an increase of HKD 109,833,000 or 109.3% compared to HKD 100,443,000 for the same period in 2022[2] - Profit before tax increased to HKD 274,958, a significant rise of 102.5% from HKD 135,395 in the previous year[7] - Total comprehensive income for the period was HKD 198,189, recovering from a loss of HKD 16,659 in the same period last year[8] - The company reported a profit attributable to equity holders of HKD 211,201,000 for the six months ended June 30, 2023, compared to HKD 99,851,000 for the same period in 2022, representing a significant increase of 111.1%[25] - The total tax expense for the period was HKD 64,682,000, significantly higher than HKD 34,952,000 in the previous year[23] Dividends and Shareholder Returns - The company declared an interim dividend of HKD 0.06 per share for the six months ended June 30, 2023, up from HKD 0.037 for the same period in 2022[2] - The interim dividend declared for the six months ended June 30, 2023, is HKD 0.06 per share, up from HKD 0.037 per share in the same period last year, reflecting a 62.2% increase[28] - The company repurchased a total of 2,048,000 shares at a total cost of approximately HKD 5,523,000 (before expenses) during the six months ended June 30, 2023[93] - The repurchase of shares was executed under the authorization received at the annual general meetings held on May 24, 2022, and May 30, 2023, aimed at enhancing the net asset value per share and earnings per share for shareholders[93] Market and Operational Insights - The company is experiencing a steady and continuous increase in demand for its products, primarily driven by global digitalization trends, which are accelerating consolidation in the dental industry[1] - The number of digital solution cases produced in mainland China increased to approximately 373,985, a rise of 50.9% compared to 247,887 cases in the same period of 2022, driven by continued adoption of intraoral scanners by customers[5] - The company continues to focus on expanding its product offerings and market presence, particularly in the dental equipment sector[12] - The company aims to fully leverage future opportunities to further strengthen its fundamentals[1] - The company aims to establish a new business unit in Vietnam to serve mid to large dental clinic chains in the North American market[52] - The company continues to focus on digitalization trends in the dental industry to capture market share and enhance customer experience[50] Assets and Liabilities - Non-current assets as of June 30, 2023, totaled HKD 2,289,553, slightly up from HKD 2,273,309 at the end of 2022[9] - Current assets increased to HKD 1,408,230 from HKD 1,265,746 at the end of 2022, driven by higher trade receivables[9] - The company reported a net asset value of HKD 2,484,207, an increase from HKD 2,333,533 at the end of 2022[10] - The company's property, plant, and equipment value increased to HKD 656,109,000 as of June 30, 2023, from HKD 651,079,000 at the end of 2022, indicating a slight growth[29] - Goodwill increased to HKD 1,147,444,000 as of June 30, 2023, compared to HKD 1,132,420,000 at the end of 2022, showing a growth of 1.3%[30] - Trade receivables rose to HKD 615,708,000 as of June 30, 2023, from HKD 565,828,000 at the end of 2022, marking an increase of 8.8%[32] - Trade payables decreased to HKD 69,342,000 as of June 30, 2023, from HKD 75,598,000 at the end of 2022, reflecting a decline of 8.2%[34] - The company reported bank borrowings of HKD 647,404,000 as of June 30, 2023, compared to HKD 630,180,000 at the end of 2022, indicating an increase of 2.9%[36] Costs and Expenses - Selling and distribution expenses increased by about 6.0% to approximately HKD 201,369,000, accounting for about 12.6% of total group revenue[63] - Administrative expenses rose by approximately 3.6% to about HKD 376,054,000, representing about 23.5% of total group revenue[64] - The company’s financing costs rose to HKD 20,783, compared to HKD 8,895 in the previous year, indicating increased borrowing costs[7] - Financing costs increased by approximately 133.6% to about HKD 20,783,000, accounting for about 1.3% of total group revenue[66] Employee and Governance - The total employee cost for the six months ended June 30, 2023, was approximately HKD 725,358,000, compared to HKD 703,475,000 for the same period in 2022[88] - As of June 30, 2023, the company employed a total of 6,860 staff, an increase from 6,830 as of December 31, 2022[87] - The company has complied with the corporate governance code as per the Listing Rules during the six months ended June 30, 2023[95] - The audit committee, consisting of independent non-executive directors, reviewed the interim results for the six months ended June 30, 2023[96] Risks and Future Outlook - The company faces various business risks, including global economic fluctuations and geopolitical risks, which may adversely affect its financial condition and operating performance[80] - The company is optimistic about the long-term prospects in the Greater China market, driven by government procurement measures and digitalization trends[54] - The company aims to strengthen its global leadership position through strategic collaborations, acquisitions, and partnerships to expand its product offerings and distribution networks[58]

Financial Performance - For the year ended December 31, 2022, the revenue was approximately HKD 2,830 million, a decrease of about 4.2% compared to HKD 2,955 million in 2021[13] - The gross profit margin for the year ended December 31, 2022, was approximately 48.9%, down from 52.5% in 2021, with gross profit decreasing by about 10.8% to HKD 1,383 million[13] - EBITDA for the year ended December 31, 2022, was approximately HKD 463 million, a decrease of 26.0% from HKD 626 million in 2021[13] - Net profit for the year ended December 31, 2022, was approximately HKD 221 million, a decrease of about 38.8% compared to HKD 360 million in 2021[13] - Basic earnings per share for the year ended December 31, 2022, were HKD 0.231, down approximately 38.7% from HKD 0.377 in 2021[13] - For the six months ended December 31, 2022, the company reported revenue of HKD 1,401,596,000, a decrease of 1.9% compared to HKD 1,428,492,000 for the same period in 2021[14] - The gross profit for the same period was HKD 687,972,000, reflecting a decline of 1.1% from HKD 695,334,000, with a gross margin of 49.1%[14] - EBITDA increased by 14.6% to HKD 247,422,000, with an EBITDA margin of 17.7%, up from 15.1% in the previous period[14] - Net profit for the six months ended December 31, 2022, was HKD 120,106,000, a significant increase of 19.6% from HKD 100,443,000[14] Market Performance - The European market contributed 41.7% to the total revenue, making it the largest market for the company in terms of revenue[8] - Sales in Europe for the year were HKD 1,180,604,000, down 10.3%, while North America reported sales of HKD 709,317,000, a slight decrease of 1.3%[16] - The Greater China market recorded revenue of approximately HKD 666,659,000 for the year ended December 31, 2022, a decrease of about HKD 32,587,000 compared to the previous year, accounting for approximately 23.6% of total revenue[32] - The decline in the Greater China market revenue was partly due to a 4.1% depreciation of the Renminbi against the Hong Kong Dollar[32] - The overall sales in Europe increased by 4.9% in original currency terms, driven by higher consumer spending on dental specialty treatments and the adoption of intraoral scanners, which saw a sales growth of 13.6%[29] Strategic Initiatives - The company plans to further invest in production facilities in Dongguan and Vietnam to enhance its production capabilities and R&D levels[8] - The company aims to leverage new production facilities in Vietnam to establish a new business unit specifically serving mid-to-large dental clinic chains in the U.S. market[31] - The company is optimistic about the mainland China market's prospects, especially with recent government procurement measures aimed at price regulation and transparency[8] - The company plans to enhance its product offerings in the Greater China region, including expanding mid-range products and transparent aligners[32] - The company has positioned itself as a pioneer in providing comprehensive digital solutions in the dental industry, ready to capitalize on the accelerating digitalization trend[29] Expenses and Costs - Selling and distribution expenses increased by approximately 4.3% to about HKD 374,987,000, representing 13.3% of total revenue, compared to 12.2% in the previous year[39] - Administrative expenses rose by approximately 0.7% to about HKD 702,228,000, accounting for 24.8% of total revenue, up from 23.6% in the previous year[40] - Financing costs increased by approximately 13.9% to about HKD 26,270,000, representing 0.9% of total revenue, compared to 0.8% in the previous year[42] Cash Flow and Capital Expenditure - Net cash generated from operating activities decreased to approximately HKD 258,276,000 in 2022 from HKD 525,144,000 in 2021, primarily due to a decrease in net profit and an increase in income tax paid by approximately HKD 54,261,000[50] - The company's cash and cash equivalents as of December 31, 2022, were approximately HKD 444,377,000, down from HKD 633,157,000 in 2021[49] - Total capital expenditure for the year was approximately HKD 185,367,000, mainly for upgrading production facilities, with an additional investment of approximately HKD 47,259,000 in cutting-edge technology machinery[53] Shareholder Information - The board proposed a final dividend of HKD 0.044 per share for the year ended December 31, 2022, consistent with the previous year[13] - The group reported a mid-term dividend of HKD 0.037 per ordinary share for the six months ended June 30, 2022, compared to HKD 0.075 and a special dividend of HKD 0.050 for the same period in 2021[91] - As of December 31, 2022, the company's distributable reserves were approximately HKD 516.2 million, an increase from approximately HKD 494.0 million in 2021[96] Corporate Governance - The board consists of 10 members, including 6 executive directors and 4 independent non-executive directors[69] - The company has adopted a code of conduct for directors' securities trading, ensuring compliance with the standards set out in the listing rules[141] - The independent non-executive directors confirmed that the related party transactions were conducted on normal commercial terms and were fair and reasonable to shareholders[131] - The company has adhered to all applicable principles and code provisions of the corporate governance code during the reporting year[139] Risk Management - The company has developed and adopted clear risk management procedures and guidelines to identify, assess, and manage significant risks[165] - An external professional service company has been appointed to review the risk management and internal control systems annually[165] - The audit committee reported no significant internal control deficiencies following the review of the risk management system[165] Research and Development - The company invested approximately HKD 40,096,000 in research and development costs, representing about 3.1% of total revenue, up from 2.8% in 2021[53] - New product development initiatives are underway, focusing on innovative dental equipment expected to launch in Q3 2023[83] Employee Information - The group employed a total of 6,830 full-time employees as of December 31, 2022, an increase from 6,596 in 2021[67] - The total employee costs (excluding directors and senior management) amounted to approximately HKD 1,359,158,000 for the year ended December 31, 2022, compared to HKD 1,322,111,000 in 2021[67]